Clarient, Inc. provides oncology testing and diagnostic services in the United States. The company focuses on breast cancer testing, breast cancer recurrence testing, colon cancer testing, KRAS in colorectal cancer, KRAS and BRAF testing in colorectal cancer, KRAS mutation analysis, KRAS mutation testing, and pulmotype test. Its tests include ALK Rearrangement by FISH, BRAF, BRAF V600 mutation-melanoma, EGFR mutation analysis, KRAS and BRAF, KRAS mutation analysis, Mammostrat, and PI3K. The company also develops diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Its customers include pathologists, oncologists, hospitals, and biopharmaceuti...
Aliso Viejo, CA 92656-1460
Founded in 1993
Clarient Diagnostic Services, Inc., Clarient, Inc., Neogenomics Inc. - M&A Call
Oct 21 15
To discuss the agreement to acquire Clarient, Inc., and its wholly-owned subsidiary Clarient Diagnostic Services, Inc.
Clarient and Glaxo Smith Kline to Create a Force in Cancer Testing
Oct 9 14
Clarient and Glaxo Smith Kline will create a force in cancer testing. GE Healthcare, Clarient and GSK will certify laboratories around the world to perform cancer diagnostic tests with initial network labs expected in 2015. Clarient's own laboratory expertise includes immuno histochemistry (IHC), flow cytometery, qPCR, (fluorescent) in-situ hybridization ([F]ISH), cytogenetic karyotyping, microarrays, and next-generation sequencing (NGS). Lab testing networked by GE Healthcare and Clarient will focus initially on 70 melanoma-specific mutations, including the companion diagnostics (CDx)-targeted BRAF V600E and V600K genes. Testing performed at networked labs will feed an associated data analytics service to be made available by GE Healthcare as a subscription. GSK will presumably be provided the same service to aid its activities in biopharmaceutical development. The GE-Clarient-developed lab and data analytics service will be available to clients including pharmaceutical market participants, payers and other healthcare organizations.